Optimization of particle size and encapsulation efficiency of vancomycin nanoparticles by response surface methodology

Pharmaceutical Development and Technology

Volumn 19, Issue 8, 2014, Pages 987-998

  Honary, Soheyla ^a,c   Ebrahimi, Pouneh ^b   Hadianamrei, Roja ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GOLESTAN UNIVERSITY   (Iran)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Chitosan; Nanoparticle; Optimization; Response surface methodology; Vancomycin

Indexed keywords

CHITOSAN; NANOPARTICLE; VANCOMYCIN;

ARTICLE; ENCAPSULATION; GELATION; LIGHT SCATTERING; PARTICLE SIZE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RESPONSE SURFACE METHOD; SPECTROPHOTOMETER; ULTRACENTRIFUGATION;

ANTI-BACTERIAL AGENTS; CHITOSAN; DRUG CARRIERS; NANOPARTICLES; PARTICLE SIZE; POLYPHOSPHATES; VANCOMYCIN;

EID: 84890357020     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.846375     Document Type: Article

References (38)

1. Huh AJ, Kwon YJ. ''Nanoantibiotics'': A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release 2011;156:128-145
2. Chakraborty SP, Mahapatra SK, Sahu SK, et al. Internalization of Staphylococcus aureus in lymphocytes induces oxidative stress and DNA fragmentation: Possible ameliorative role of nanoconjugated vancomycin. Oxid Med Cell Longev 2011. doi: 10.1155/2011/ 942123
3. Chakraborty SP, Sahu SK, Mahapatra SK, et al. Nanoconjugated vancomycin: New opportunities for the development of anti-VRSA agents. Nanotechnology 2010;21:1-9
4. Chakraborty SP, Mahapatra SK, Sahu SK, et al. Nitric oxide mediated Staphylococcus aureus pathogenesis and protective role of nanoconjugated vancomycin. Asian Pac J Trop Biomed 2011;1: 102-109
5. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 2006;166:2138-2144
6. Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-Associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007;29:1107-1115
7. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agent Chemother 2008;52: 1330-1336
8. Sivagnanam S, Deleu D. Red man syndrome. Crit Care 2003;7: 119-120
9. Zhang L, Pornpattananangkul D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem 2010;17:585-594
10. Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther 2008;83:761-769
11. Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009;86:215-223
12. Patel JK, PJivani N. Chitosan based nanoparticles in drug delivery. Int J Pharmaceut Sci Nanotech 2009;2:517-522
13. Sailaja AK, Amareshwar P, Chakravarty P. Chitosan nanoparticles as a drug delivery system. Res J Pharm Biol Chem Sci 2010;1: 474-484
14. Patel MP, Patel RR, Patel JK. Chitosan mediated targeted drug delivery system: A review. J Pharm Pharmaceut Sci 2010;13: 536-557
15. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- And nanoparticles in drug delivery. J Control Release 2004;100:5-28
16. Wang JJ, Zeng ZW, Xiao RZ, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomed 2011;6:765-774
17. Kavitha K, Keerthi TS, Mani TT. Chitosan polymer used as carrier in various pharmaceutical formulations: Brief review. Int J Appl Biol Pharmaceut Tech 2011;2:249-258
18. Li P, Wang Y, Peng Z, et al. Development of chitosan nanoparticles as drug delivery systems for 5-fluorouracil and leucovorin blends. Carbohyd Polym 2011;85:698-704
19. Turan K, Nagata K. Chitosan-DNA nanoparticles: The effect of cell type and hydrolysis of chitosan on in vitro DNA transfection. Pharm Dev Technol 2006;11:503-512
20. Luangtana-Anan M, Opanasopit P, Ngawhirunpat T, et al. Effect of chitosan salts and molecular weight on a nanoparticulate carrier for therapeutic protein. Pharm Dev Technol 2005;10: 189-196
21. Rabea EI, Badawy ME, Stevens CV, et al. Chitosan as antimicrobial agent: Applications and mode of action. Biomacromolecules 2003;4: 1457-1465
22. Chung YC, Wang HL, Chen YM, Li SL. Effect of abiotic factors on the antibacterial activity of chitosan against waterborne pathogens. Bioresour Technol 2003;88:179-184
23. Qi L, Xu Z, Jiang X, et al. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res 2004;339: 2693-2700
24. Don TM, Chen CC, Lee CK, et al. Preparation and antibacterial test of chitosan/PAA/PEGDA bi-layer composite membranes. J Biomat Sci Polym 2005;16:1503-1519
25. Loveymi BD, Jelvehgari M, Zakeri-Milani P, Valizadeh H. Design of vancomycin RS-100 nanoparticles in order to increase the intestinal permeability. Adv Pharm Bull 2012;2:43-56
26. Loveymi BD, Jelvehgari M, Zakeri-Milani P, Valizadeh H. Statistical optimization of oral vancomycin-eudragit RS nanoparticles using response surface methodology. Iran J Pharm Res 2012;11: 1001-1012
27. Loveymi BD, Jelvehgari M, Zakeri-Milani P, Valizadeh H. The characteristics and improved intestinal permeability of vancomycin PLGA-nanoparticles as colloidal drug delivery system. Colloids Surf B Biointerfaces 2013;103:174-181
28. Chuah LH, Billa N, Roberts CJ, et al. Curcumin-containing chitosan nanoparticles as a potential mucoadhesive delivery system to the colon. Pharm Dev Technol 2013;18:591-599
29. Modaresi SMS, Ejtemaei Mehr S, Faramarzi MA, et al. Preparation and characterization of self-Assembled chitosan nanoparticles for the sustained delivery of streptokinase: An in vivo study. Pharm Dev Technol 2013; Early Online: 1-5. DOI: 10.3109/ 10837450.2013.813542
30. Eriksson L, Johansson E, Kettaneh-wold N, et al. Design of experiments: Principles and applications. Umea: Umetrics academy; 2008:8-24
31. Czitrom V. One-factor-At-A-Time versus designed experiments. Am stat 1999;53:126-131
32. Anderson-cook CM, Borror CM, Montgomery DC. Response surface design evaluation and comparison. J Stat Plan Infer 2009; 139:629-641
33. Box GEP, Draper NR. Empirical model building and response surfaces. New York: John Wiley and Sons; 1987:477
34. Box GEP, Behnken DW. Some new three level designs for the study of quantitative variables. Technometrics 1960;2:455-475
35. Linkov I, Satterstrom FK, Kiker G, et al. From comparative risk assessment to multi-criteria decision analysis and adaptive management: Recent developments and applications. Environ Int 2006;32: 1072-1093
36. Calvo P, Remun?án-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 1997;63:125-132
37. Yetilmezsoya K, Demirel S, Vanderbei RJ. Response surface modeling of pb(ii) removal from aqueous solution by pistacia vera l.: Box-Behnken experimental design. J Hazard Mater 2009;171: 551-562
38. Adinarayana K, Ellaiah P. Response surface optimization of the critical medium components for the production of alkaline protease by a newly isolated Bacillus sp. J Pharm Pharm Sci 2002;5: 272-278